Malcolm Duncan
Psychiatric/Mental Health · Spring, TXNPI 1033691746
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 66.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $17,329 and has fallen 53.5% since, to $8,062 in 2025. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $81.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$22K
- Alkermes, Inc.$6K
- Neurocrine Biosciences, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$801
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$765
- Johnson & Johnson$479
- plus $1K from 11 others
What the payments were for
- Consulting fees$2,6558%
- Speaking & faculty fees$14,98945%
- Travel & lodging$3,88212%
- Food & beverage$11,82235%
- Education$950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 186 | $22,325 |
| Alkermes, Inc. | 98 | $6,283 |
| Neurocrine Biosciences, Inc. | 38 | $1,510 |
| Otsuka America Pharmaceutical, Inc. | 20 | $801 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $765 |
| Johnson & Johnson | 14 | $479 |
| E.r. Squibb & Sons, L.L.C. | 14 | $417 |
| AbbVie | 4 | $254 |
| Lundbeck LLC | 8 | $160 |
| Vanda Pharmaceuticals Inc. | 4 | $160 |
| Eisai Inc. | 1 | $122 |
| Indivior Inc. | 3 | $60 |
| Alpha Cognition USA, Inc. | 1 | $36 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$16,137
- Austedo XR$11,989
- UZEDY$6,872
- ARISTADA INITIO$3,811
- LYBALVI$2,492
- INGREZZA$707
- CAPLYTA$443
- INVEGA SUSTENNA$236
- COBENFY$227
- VRAYLAR$217
- AUSTEDO$135
- Fanapt$125
- INVEGA TRINZA$124
- Dayvigo$122
- ABILIFY ASIMTUFII$121
- ABILIFY MAINTENA$121
- REXULTI$121
How this compares
$33,444 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 129 | $932,280 |
| AristadaAripiprazole Lauroxil | 205 | $731,760 |
| Austedo XrDeutetrabenazine | 63 | $429,832 |
| LybalviOlanzapine/Samidorphan Malate | 209 | $350,557 |
| IngrezzaValbenazine Tosylate | 40 | $282,564 |
| UzedyRisperidone | 37 | $115,772 |
| Abilify MaintenaAripiprazole | 27 | $80,692 |
| Invega SustennaPaliperidone Palmitate | 31 | $78,379 |
| RexultiBrexpiprazole | 48 | $73,706 |
| NuedextaDextromethorphan Hbr/Quinidine | 29 | $49,001 |
| Divalproex Sodium ErDivalproex Sodium | 575 | $43,169 |
| Aripiprazole | 535 | $39,381 |
| Oxcarbazepine | 232 | $37,644 |
| VraylarCariprazine Hcl | 11 | $34,409 |
| Clozapine | 260 | $26,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy | $22,325 | $1,477,884229 claims |
| Alkermes, Inc.Aristada, Lybalvi | $6,283 | $1,082,317414 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,510 | $282,56440 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $801 | $154,39875 claims |
| Johnson & JohnsonInvega Sustenna | $479 | $78,37931 claims |
| AbbVieVraylar, Namzaric | $254 | $49,10834 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $21 | $49,00129 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $765 | $19,35511 claims |
| Lilly USA, LLCOlanzapine | $19 | $8,430351 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Spring
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
- Jaime Nelson DensonAustin$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.